News

Mereo BioPharma Group plc's ORBIT study for setrusumab in osteogenesis imperfecta moves to final analysis by 2025. Click for ...
Analysts are keeping the faith in Ultragenyx’s brittle bone disease medicines despite the monoclonal antibody failing to score an early outright win in an ongoing phase 3 trail. | Analysts are keeping ...
Packed aboard Tianzhou 9 was 7.2 tons (6.5 metric tons) of cargo, including 1.65 tons (1.5 metric tons) of food for the three ...
Partners Ultragenyx and Mereo BioPharma saw their stocks drop by 21% and 30%, respectively, after announcing that the Phase ...
As Axiom Mission 4 comes to a close, the International Space Station serves Group Captain Shubhanshu Shukla and the rest of the Ax-4 crew as a premier laboratory for space research ...
Ultragenyx (RARE) stock and Mereo (MREO) stock are in selloff after a trial update on thier bone disorder therapy UX143. Read ...
You might not know is that fifty-five years later, Utahns are paving the way for a return back to the moon with ingenuity and ...
Ultragenyx and Mereo stocks crashed Thursday after their treatment for brittle bone disease missed its mark in a second ...
On Monday, some employees at ORD, the largest office in the agency, began receiving emails saying they’d been assigned new ...
Want 50GBps of sequential performance? HighPoint's 7604A x16 PCIe 5.0 NVMe RAID card sporting four full-speed M.2 slots can ...